First of all, what we're aiming to improve is bringing the regulation of these products under a single framework under the Food and Drugs Act. Currently there are different categories of these products that are regulated under different acts that have different requirements and different timelines for the review. We'd like to consolidate that under one act.
The other change is that we're creating a new set of regulations that are a lot more appropriate for these types of products versus the regulations that we have currently. They will have requirements that are more risk-based and will also have different mechanisms for these products to be reviewed and enter the market. It would facilitate access to broader ranges of products.
One of the examples is the use of a foreign decision pathway. That would allow for products to come in through a process that's simpler, more streamlined and less costly for industry.